Integrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer
Open Access
- 6 January 2026
- journal article
- research article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1)
Abstract
Breast cancer remains a leading cause of cancer-related mortality among women worldwide, highlighting the need for safer multitarget therapies. Genistein (Keywords
This publication has 80 references indexed in Scilit:
- Integrated computational approach revealed the potential inhibitory effect of xanthone derivatives against Marburg virus nucleocapsidVirusDisease, 2025
- Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsCurrent Breast Cancer Reports, 2025
- Molecular docking, drug-likeness properties, and toxicity prediction of alkaloidal phytoconstituents of piper longum against monoamine oxidase enzyme-A as an anti-depressive agentDiscover Chemistry, 2025
- Molecular docking and pharmacokinetic evaluations of curcumin-based scaffolds as MDM2-p53 inhibitorsDiscover Chemistry, 2025
- Toxicity prediction and analysis of flavonoid apigenin as a histone deacetylase inhibitor: an in-silico approachIn Silico Pharmacology, 2023
- ESR1 activating mutations: From structure to clinical applicationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Natural Products in Cancer Therapy: Past, Present and FutureNatural Products and Bioprospecting, 2021
- Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycinBreast Cancer Research and Treatment, 2015
- Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulinBiochimie, 2013
- Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell linesJournal of Cancer Research and Clinical Oncology, 2000